User Group Meeting “Highly Informative and Incredibly Valuable,” Says D360 Clients ST. LOUIS, MO – Oct. 17, 2014 – Certara’s Second Annual D360™ User Group Meeting (UGM) was described as “Highly Informative” and “Incredibly Valuable” by top pharmaceutical scientists who attended. The meeting, held at the Boston’s Royal Sonesta Hotel on October 8 and 9, … Continued
Nearly half of drug candidates fail because of inadequate safety in pre-clinical testing, representing an expensive loss of investment and lost opportunity. Often, drugs are found to cause toxicity through off-target activity. Therefore, understanding how drugs interact with their target receptors, and minimizing off-target activity is crucial to developing effective medications. Over my career, I’ve … Continued
Have you heard the FDA will require electronic submissions that use CDISC standardized study data? In my work at Certara, I’ve noticed there’s a lot of confusion, and even significant apprehension, surrounding this issue. To combat the misconceptions about what these regulations will mean for drug developers, I’ve compiled a list of common questions (and … Continued
Welcome! We’re excited to launch Certara’s blog. This gives us a chance to comment on important news and topics in the rapidly changing world of drug development. Our blog will offer more than one contributor to ensure you get multiple perspectives on the issues impacting us all. We hope that you’ll share your comments about our solutions … Continued
Historically, drugs have been selected using various methods (eg, biological and chemical screens). Candidate drugs were often pushed into the clinic with only a rudimentary understanding of the link between drug exposure and resultant effect(s). As a consequence, drug development has been inefficient by relying on trial and error at the clinical stage, not to … Continued
Certara consultants will present a total of five seminars and five posters at ACoP5 being held from Oct. 12-15 in Las Vegas, Nev. ST. LOUIS, MO – Oct. 8, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that its Simcyp and Pharsight consultants will present a total of … Continued
